Published in Am J Pathol on May 12, 2009
Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol (2011) 1.08
Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) (2011) 1.07
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol (2013) 0.99
Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid. EMBO Mol Med (2013) 0.91
Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis. Nutrients (2015) 0.85
Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the Wnt signaling pathway. PLoS Genet (2014) 0.84
Differential effects of pioglitazone on advanced atherosclerotic lesions. Am J Pathol (2009) 0.78
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis (2015) 0.76
PPARγ and Its Role in Cardiovascular Diseases. PPAR Res (2017) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2000) 5.07
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab (2008) 4.34
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest (1994) 3.97
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 3.00
Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem (1997) 2.95
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2001) 2.85
Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation (1999) 2.84
Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature (1995) 2.79
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care (2000) 2.58
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med (2001) 2.43
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation (2007) 2.04
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol (2008) 1.81
Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol (2001) 1.78
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther (2002) 1.72
Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem (1991) 1.71
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.35
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther (2000) 1.30
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation (2001) 1.25
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract (2002) 1.18
Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol (1997) 1.17
Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation (2006) 1.12
PROactive: time for a critical appraisal. Eur Heart J (2008) 1.11
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis (2001) 1.08
Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor. J Immunol (2008) 1.08
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol (2004) 1.07
Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology (2001) 1.07
Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol (2008) 1.07
Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol (2006) 1.05
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab (2003) 1.02
Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc Med (2004) 0.99
Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol (2008) 0.97
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension (2002) 0.97
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism (2006) 0.96
Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism (2004) 0.96
Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine (2002) 0.96
Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol (2007) 0.94
Low-density lipoprotein receptor--its structure, function, and mutations. Semin Vasc Med (2004) 0.93
Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs (2006) 0.89
Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis (2006) 0.88
Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab (2002) 0.87
Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques. J Cardiovasc Pharmacol (2006) 0.86
Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens (1996) 0.85
Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase. FEBS Lett (2003) 0.82
Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis (2007) 0.81
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract (2005) 0.81
Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta (2004) 0.79
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med (2010) 4.42
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol (2013) 3.61
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med (2005) 3.45
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem (2002) 3.17
Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke (2013) 2.53
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (2004) 2.26
HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 2.25
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Inflammation in atherosclerosis and implications for therapy. Circulation (2004) 1.71
Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity (2007) 1.55
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol (2010) 1.53
A wet-primed extracorporeal membrane oxygenation circuit with hollow-fiber membrane oxygenator maintains adequate function for use during cardiopulmonary resuscitation after 2 weeks on standby. Crit Care Med (2005) 1.48
Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli. Am J Physiol Heart Circ Physiol (2010) 1.46
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes (2009) 1.46
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare? Circulation (2002) 1.42
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. AIDS Read (2007) 1.40
The editor's roundtable: JUPITER follow-up. Am J Cardiol (2011) 1.39
Update on statins: 2003. Circulation (2004) 1.37
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord (2009) 1.18
Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol (2008) 1.15
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol (2002) 1.14
CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol (2004) 1.13
Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet (2009) 1.11
Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm (2009) 1.07
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J (2009) 1.04
Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation (2004) 1.03
The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol (2003) 1.02
Vγ4 γδ T cell-derived IL-17A negatively regulates NKT cell function in Con A-induced fulminant hepatitis. J Immunol (2011) 1.00
Endothelialization and patency of RGD-functionalized vascular grafts in a rabbit carotid artery model. Biomaterials (2012) 1.00
Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med (2003) 1.00
Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem (2009) 0.98
Advances in the use of tocols as drug delivery vehicles. Pharm Res (2006) 0.98
Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem (2002) 0.95
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics (2004) 0.95
Regulatory role of Vγ1 γδ T cells in tumor immunity through IL-4 production. J Immunol (2011) 0.95
Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation (2004) 0.95
No evidence for neo-oogenesis may link to ovarian senescence in adult monkey. Stem Cells (2013) 0.95
Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol (2010) 0.95
Protein 3-nitrotyrosine in complex biological samples: quantification by high-pressure liquid chromatography/electrochemical detection and emergence of proteomic approaches for unbiased identification of modification sites. Methods Enzymol (2008) 0.95
Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite. J Lipid Res (2006) 0.95
Building a transcontinental affiliation: a new model for academic health centers. Acad Med (2005) 0.94
Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol (2007) 0.94
Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. Am J Pathol (2013) 0.92
Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res (2003) 0.92
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem (2003) 0.90
Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med (2002) 0.90
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res (2012) 0.88
Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. J Biol Chem (2007) 0.87
Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. Am J Physiol Cell Physiol (2004) 0.87
Improving lipid goal attainment: is it enough? Circulation (2009) 0.87
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol (2006) 0.86
Statin therapy and the elderly: SAGE advice? Circulation (2007) 0.85
Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins Other Lipid Mediat (2006) 0.84
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation (2002) 0.84
Activation of liver X receptor induces macrophage interleukin-5 expression. J Biol Chem (2012) 0.84
Tyrosine nitration in prostaglandin H(2) synthase. J Lipid Res (2002) 0.83
Danhong injection inhibits the development of atherosclerosis in both Apoe⁻/⁻ and Ldlr⁻/⁻ mice. J Cardiovasc Pharmacol (2014) 0.82
Past, present, and future standards for management of dyslipidemia. Am J Med (2004) 0.82
Characterization of a cellular denitrase activity that reverses nitration of cyclooxygenase. Am J Physiol Heart Circ Physiol (2013) 0.81
A novel tylophorine analog W-8 up-regulates forkhead boxP3 expression and ameliorates murine colitis. J Leukoc Biol (2012) 0.81
Dyslipidemia and the vulnerable plaque. Prog Cardiovasc Dis (2002) 0.81
Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease. Curr Hypertens Rev (2009) 0.80
Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. Hypertension (2007) 0.80
Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques. Drug Dev Ind Pharm (2011) 0.80
Physical evidence for substrate binding in preventing cyclooxygenase inactivation under nitrative stress. J Am Chem Soc (2010) 0.80
Identification of interferon-γ as a new molecular target of liver X receptor. Biochem J (2014) 0.79